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eroning TG2 out of the chondrocyte cytosol. Recombinant TG2, 
but not IL-8, retinoic acid or recombinant FXlIIA, retained the ca- 
pacity to induce chondrocyte hypertrophy in FXlIIA knocked-down 
chondrocytes. During chondrocyte maturation in vitro, immuocy- 
tochemistry revealed distinct populations of FXlllA-staining non- 
enlarged cells early in the process, and enlarged TG2-staining 
cells late in the process, suggesting networking between distinct 
cell subsets. Stimulation of bovine cartilage explants revealed 
correlations with Iocalizations of FXlIIA and TG2 and the pattern 
of type X collagen expression. Expression of FXlIIA cDNA point 
and truncation mutants, and stimulation with recombinant soluble 
FXlIIA, revealed the necessity for an intact calcium-binding do- 
main Thr458-Glu495for FXlIIA to induce chondrocyte hypertrophy. 
FXlIIA Ala 457, one of the amino acids demonstrated to directly 
bind calcium, also was essential for induction of TG2 release and 
chondrocyte maturation. Last, exogenous wild type FXlIIA stimu- 
lated the activation of p38, a known signal transducer of chondro- 
cyte hypertrophy, and did so dependent upon FXlIIA Ala 457. 
Conclusions: FXlIIA expression transduces chemokine and 
retinoic acid-induced chondrocyte hypertrophy. FXlIIA induction 
of hypertrophic differentiation depends on FXlIIA having a com- 
plete calcium binding domain (Thr458Glu495), Ala 457, to bind cal- 
cium directly through its main chain oxygen, and the release of 
TG2. Our findings suggest that a subset of FXlllA-expressing 
chondrocytes networks with distinct TG2-expressing cells to pro- 
mote chondrocyte maturation in OA cartilage that mediates dis- 
ease progression. 
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It is still largely unknown what causes osteoarthritis (OA). How- 
ever, it is thought hat developmental processes important in em- 
bryonic development are recapitulated in osteoarthritic cartilage. 
Several members of the wnt and frizzled (Fzd) families are in- 
volved in embryonic development of cartilage and bone. 
Aim of study: To perform a longitudinal expression analysis of 
wnt/Fzd- and related genes during development of an experimen- 
tal model for OA and to verify the expression of selected genes in 
human tissue obtained from knee replacement surgery. 
Methods: Experimental OA was induced by injecting collagenase 
intra-articularly into murine knee joints twice on alternate days, 
thus causing local instability. Cartilage and synovial tissue were 
isolated at 7 days, 21 days and 42 days after induction, mRNA 
was isolated and analyzed using Taqman Low Density Arrays, to 
determine the expression level of 48 genes (Table1) in 8 sam- 
ples simultaneously. Expression of selected genes was tested on 
cartilage from human OA and control patients. 
Results: Several genes from the wnt and Fzd families, as well as 
genes that are involved in wnt-signaling, were regulated in the OA 
model. Wnt-induced secreted protein-1 (WISP-l) was strongly 
upregulated compared to control (left) knee joints. In the syn- 
ovium, expression of WISP1 at day 7, 21 and 42 was increased 
39-fold, 16-fold and 9-fold respectively. In the cartilage, WISP1 
expression was significantly increased at day 7 and 21 (2.5-fold 
and 2.8-fold respectively). In a model for acute arthritis, WISP1 
was not regulated in the cartilage, indicating specificity for OA 
processes. 
In the OA synovium, wnt16 and wnt2b were also strongly upreg- 
ulated at day 7, 21 and 42, (128-, 180- and 90-fold and 80-, 8 
and 1-fold respectively). The increased cartilage expression of 
WISP1 in experimental OA was validated in human OA cartilage. 
In concordance with the experimental OA, WISP1 expression in 
human knee joint cartilage was significantly upregulated (2.65 
fold, p<0.03) compared to control cartilage. 
Table 1. Determined genes 
Frizzled WNT 
Marker genes WNT genes genes related genes 
ADAMTS4 IL-18 
BMP4 IL-lb 
Coil Xal IL-6 
Coil la2 MMP-13 
Coil Ilal TGFb3 
Axin2 LRP6 Fzd3 Fzd7 Wnt2b Wnt7b 
Dickkopf3 Sfrpl Fzd4 Fzd8 Wnt2 Wnt8a 
Dishevelled 1 Sfrp2 Fzd5 Fzdl0 Wnt3a Wnt8b 
Frzb Siah2 Fzd6 Wnt3b Wntl0a 
Indian Hedgehog Wisp1 Wnt4 Wntl0b 
LRP5 Wnt5a Wntl 1 
Wnt5b Wnt14 
Wnt6 Wnt15 
Wnt7a Wnt16 
Conclusions: These results show that during experimental OA, 
Wnt-related processes are regulated as was indicated by the 
markedly increased synovial expression of wnt2b and wntl 6. An- 
other strong indication is the enhanced expression of WISP1 
in synovium and cartilage. This does not only signify that wnt- 
signaling pathways are activated, but it also indicates that the in- 
creased expression of WISP1 may have inhibiting effects on ma- 
trix production by chondrocytes in OA cartilage, since it has been 
described that WISP1 can inhibit the matrix producing chondro- 
cyte phenotype. 
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Aim: Signals generated by the extracellular matrix and by growth 
factors promote cell survival. Loss of survival signals during the 
development of arthritis could contribute to the death of chondro- 
cytes which has been observed in cartilage in OA and inflamma- 
tory arthritis. The aim of this study was to better define signaling 
mechanisms responsible for chondrocyte cell death under con- 
ditions where matrix and growth factor survival signals are defi- 
cient. 
Methods: A model system was developed to deprive chondro- 
cytes of growth factor and matrix signals. Chondrocytes were re- 
moved from normal human articular cartilage by enzymatic di- 
gestion and plated at low density (to reduce autocrine/paracrine 
growth factor signaling) in serum-free media on poly-L-lysine (no 
matrix signals) or fibronectin (FN) as a matrix control. Survival 
was assessed after 24 hours in the presence of nM to I~M doses 
of a panel of over 50 inhibitors of various signaling pathways as 
well as reagents that modify reactive oxygen species (ROS) pro- 
duction. 
Results: Significant cell death (60% of the plated cells) was 
noted on poly-L-lysine while no cell death was noted under similar 
culture conditions with cells plated on FN. Cells on poly-L-lysine 
had a 2-fold increase in ROS production, measured using a flu- 
orescent probe (DCFDA), compared to cells on FN. Cell death 
on poly-L-lysine could be completely inhibited with the addition 
of either antioxidants (Tiron, MnTBAP, or N-acetyl-cysteine) or 
inhibitors of specific protein kinase C (PKC) isoforms including 
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PKC-I~I. Inhibitors of nitric oxide production did not promote sur- 
vival and an inhibitor of PKC-5 caused cell death on both poly- 
L-lysine and FN. PKC-I~I was noted to translocate from the cy- 
tosol to the particulate membrane after plating on poly-L-lysine 
and this translocation was inhibited by the addition of an antiox- 
idant. Time-course analyses implicated endogenous ROS pro- 
duction as a secondary messenger leading to PKC-I~I activation 
and subsequent chondrocyte cell death. Cell survival on poly-L- 
lysine was improved by 50% in the presence of oligomycin which 
suggested the electron transport chain of the mitochondria as a 
candidate for the production ROS. However, cell death on poly- 
L-lysine was not associated with DNA fragmentation or activation 
of caspase activity consistent with necrotic rather than apoptotic 
cell death. Significant ATP depletion was noted in chondrocytes 
on poly-L-lysine suggesting a potential mechanism for a switch 
from apoptosis (which requires energy) to necrosis. 
Conclusion:  These results support a novel mechanism for chon- 
drocyte death when matrix and growth factor signals are lost that 
includes increased ROS production and activation of PKC-I~I. The 
signaling was PKC isoform specific since PKC-5 inhibition re- 
sulted in cell death suggesting it is required for survival signaling 
whereas activation of PKC-I~I promoted chondrocyte cell death. 
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The Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) 
was a randomized double-blind placebo (P)- and celecoxib (CE)- 
controlled trial of 1583 OA patients designed to evaluate the effi- 
cacy of glucosamine (G), chondroitin sulfate (CS), and combina- 
tion (G+CS) in improving osteoarthritis (OA) knee pain. We calcu- 
lated the sample size needed to declare as statistically significant 
the treatment effect sizes observed in GAIT for each active treat- 
ment group compared with placebo, assuming power of 90% and 
two-sided alpha of 5% for each comparison. Sample sizes re- 
quired for 1) the primary outcome measure, which classified pa- 
tients as a treatment responder if they had a 20% reduction in the 
Western Ontario and McMaster University Osteoarthritis Index 
(WOMAC) summed pain subscale at the end of treatment com- 
pared with the baseline measurement, 2) response using the Out- 
come Measures in Rheumatology Clinical Trials -Osteoarthritis 
Research Society International (OMERACT-OARSI) criteria, 3) 
change in WOMAC pain from baseline to end of follow-up, 4) 
change in WOMAC function and 5) change in Health Assessment 
Questionnaire (HAQ) pain. We also assessed the influence of the 
placebo response rate and baseline level of pain on the required 
sample sizes. These results are shown in the table. 
For WOMAC Pain 20% Response and OMERACT-OARSI Re- 
sponse, sample sizes decreased as the placebo response rate 
decreased. Overall, sample sizes were smaller for patients with 
moderate-to-severe knee pain due to OA than for patients with 
mild pain. OMERACT-OARSI Response generally required the 
smallest sample sizes. 
When planning randomized clinical trials of OA treatments for 
knee pain, the OMERACT-OARSI responder criteria will yield 
smaller sample size requirements. In addition, it is important to 
consider the expected level of pain patients may report at study 
entry. 
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Aim of Study: Proteinase-activated receptors (PARs) represent 
a family of seven transmembrane domain G protein coupled re- 
ceptors. They are activated by a proteolytic leavage generating 
a tethered activating ligand at the N-terminus. Four members of 
this family have been identified, and named PAR-l, -2, -3 and -4. 
PAR-2 plays a role in both neurogenic inflammation and hyperal- 
gesia by promoting the release of substance R PAR-2 was also 
recently suggested to be involved in inflammation and to induce 
the synthesis of catabolic and inflammatory factors. Until now, 
little has been reported on the involvement of this factor in hu- 
man osteoarthritic articular tissues. In this study, we investigated 
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CE vs. P G vs. P CS vs. P G+CS vs. P Placebo Response 
WOMAC Pain 20% Response 
All 992 6606 3570 2368 60.1% 
Mild Pain* 1318 27450 4278 68882 61.7% 
Moderate-to-Severe Pain# 458 808 2086 162 54.3% 
OMERACT-OARSI Response 
All 950 7544 2368 1360 56.9% 
Mild Pain* 1496 >100000 3222 7816 59.3% 
Moderate-to-Severe Pain# 332 372 1082 154 48.6% 
Change in WOMAC Pain 
All 2636 49668 >100000 2456 -86.1 
Mild Pain* 5416 5938 97228 41872 -75.6 
Moderate-to-Severe Pain# 492 1380 84296 154 -123.0 
Change in WOMAC Function 
All 1428 > 100000 81016 2262 -227.4 
Mild Pain* 2434 3590 30606 35496 -209.2 
Moderate-to-Severe Pain# 462 504 >100000 200 -291.6 
Change in HAQ Pain 
All 2546 91538 22886 1870 -16.6 
Mild Pain* 6334 8490 > 100000 6334 - 15.0 
Moderate-to-Severe Pain# 448 1320 1222 276 -22.1 
*Mild Pain: Summed WOMAC Pain Score of 125-300mm, #Moderate-to-Severe Pain: Summed WOMAC Pain Score of 301-400mm 
